

31<sup>st</sup> January 2013

## December 2012 Quarterly update and Appendix 4C

### Highlights

- Access to full data set from H-005 clinical trial
- Further review and investigations of the full data from clinical trial H-005
- Board re-constitution and appointment of new CEO
- Review of strategic options, streamlining management
- Cash balance of \$508,000 as at 31 December 2012

Prior to Christmas 2012, the Company gained access to the full data set from its clinical trial H-005. This enabled the commencement of a detailed review and investigations of the data. The review is crucial in the planning of the way ahead for the Company's HI-164 project. We have worked collaboratively with Datapharm Australia, our clinical research advisors, on the review.

The board was reduced in size and re-constituted with the appointment of new chairman, Tony Ho and the re-joining to the board of Jeremy Curnock Cook, together with continuing director Patrick Ford. The new board is committed to work towards enhancing shareholders' value. Dr. Phillip Comans joined the Company as the new CEO, replacing David Radford, bringing extensive experience and skills in managing a research organisation. Management processes were simplified to be aligned with the Company's operations.

Cash payments for the December quarter included final payments on the H-005 clinical trials. Costs were also incurred on numerous corporate shareholders meetings and planning and negotiations for a further clinical trial. As previously signalled at the Company's last annual general meeting, the Company will require further funding to mitigate risks and to broaden the Company's activities.

For more information, please contact:

Dr. Phillip Comans  
Chief Executive Officer  
Bioxyne Limited  
Mobile: +61 439 466 116

[www.bioxyne.com](http://www.bioxyne.com)

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

Bioxyne Limited

ABN

97 084 464 193

Quarter ended ("current quarter")

31 December 2012

### Consolidated statement of cash flows

	Current quarter \$A'000	Year to date (6 months) \$A'000
<b>Cash flows related to operating activities</b>		
1.1 Receipts from customers	88	274
1.2 Payments for		
(a) staff costs	(126)	(245)
(b) advertising and marketing	(8)	(17)
(c) research and development	(256)	(485)
(d) leased assets	-	-
(e) other working capital	(421)	(1,233)
1.3 Dividends received		
1.4 Interest and other items of a similar nature received	-	2
1.5 Interest and other costs of finance paid	(4)	(31)
1.6 Income taxes paid		
1.7 Other (R&D Tax Concession Proceeds)	-	1,529
<b>Net operating cash flows</b>	<b>(727)</b>	<b>(206)</b>

---

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current quarter \$A'000	Year to date (12 months) \$A'000
1.8 Net operating cash flows (carried forward)	(727)	(206)
<b>1.9 Cash flows related to investing activities</b>		
Payment for acquisition of:		
(a) businesses (item 5)		
(b) equity investments		
(c) intellectual property		
(d) physical non-current assets		
(e) other non-current assets		
<b>1.10 Proceeds from disposal of:</b>		
(a) businesses (item 5)		
(b) equity investments		
(c) intellectual property		
(d) physical non-current assets		
(e) other non-current assets		
1.11 Loans to other entities		
1.12 Loans repaid by other entities		
1.13 Cash held by subsidiary on acquisition		
<b>Net investing cash flows</b>	-	-
<b>1.14 Total operating and investing cash flows</b>	(727)	(206)
<b>Cash flows related to financing activities</b>		
1.15 Proceeds from issues of shares, options, etc.		
1.16 Proceeds from sale of forfeited shares		
1.17 Proceeds from issue of convertible notes		
1.18 Repayment of borrowings		
1.19 Dividends paid		
1.20 Cost of issuing equity	-	(65)
<b>Net financing cash flows</b>	-	(65)
<b>Net increase (decrease) in cash held</b>	(727)	(271)
1.21 Cash at beginning of quarter/year to date	1,236	780
1.22 Exchange rate adjustments to item 1.20	(1)	(1)
<b>1.23 Cash at end of quarter</b>	508	508

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Payments to directors of the entity and associates of the directors**  
**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	139
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Amounts included in item 1.24 include consultancy fees paid to directors or their nominees. All transactions with related parties have occurred on an arm's length basis.

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

**Financing facilities available**

*Add notes as necessary for an understanding of the position.*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

---

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	508	1,236
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter (item 1.23)</b>	<b>508</b>	<b>1,236</b>

**Acquisitions and disposals of business entities**

	Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1 Name of entity	-	-
5.2 Place of incorporation or registration	-	-
5.3 Consideration for acquisition or disposal	-	-
5.4 Total net assets	-	-
5.5 Nature of business	-	-

---

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Compliance statement**

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Sign here: ..... Date: 31 January 2013.  
(~~Director~~/Company secretary)

Print name: Laura Raymer

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

---

+ See chapter 19 for defined terms.